Zimmer Biomet/ZBH

$120.78

1.13%
-
1D1W1MYTD1YMAX

About Zimmer Biomet

Zimmer Biomet Holdings, Inc. is a global medical technology company. Its segments include Americas, EMEA, and Asia Pacific. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (CMFT) products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its other product category primarily includes its robotic, surgical and bone cement products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and others.

Ticker

ZBH

Sector

Healthcare

Trading on

NYSE

Industry

Medical Equipment & Supplies

CEO

Ivan Tornos

Employees

18,000

Headquarters

Warsaw, United States

Zimmer Biomet Metrics

BasicAdvanced
$24.54B
Market cap
24.43
P/E ratio
$4.89
EPS
1.04
Beta
$0.96
Dividend rate
0.8%
Dividend yield
$24.54B
1.03912
$149.25
$102.00
1.43M
$0.96
1.613
0.778
39.004
46.216
19.54%
27.513
7.32%
4.82%
8.36%
5.49%
24.431
3.319
1.967
35.486
0.72%
0.8%
0.8%
6.55%
254.47%
6.46%

What the Analysts think about Zimmer Biomet

Analyst Ratings

Majority rating from 28 analysts.
Hold

Price Targets

Average projection from 23 analysts.
13.57% upside
High $160.00
Low $109.00
$120.78
Current price
$137.17
Average price target

Zimmer Biomet Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
21.6% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$1.94B
10.64%
Net income
$419.2M
157.81%
Profit margin
21.6%
133.01%

Zimmer Biomet Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 2.11%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$1.89
$1.82
$1.65
$2.20
-
Expected
$1.64
$1.81
$1.60
$2.15
$1.87
Surprise
15.33%
0.57%
3.28%
2.11%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Zimmer Biomet stock?

Zimmer Biomet (ZBH) has a market cap of $24.54B as of April 23, 2024.

What is the P/E ratio for Zimmer Biomet stock?

The price to earnings (P/E) ratio for Zimmer Biomet (ZBH) stock is 24.43 as of April 23, 2024.

Does Zimmer Biomet stock pay dividends?

Yes, the Zimmer Biomet (ZBH) stock pays dividends to shareholders. As of April 23, 2024, the dividend rate is $0.96 and the yield is 0.8%. Zimmer Biomet has a payout ratio of 19.54% on a trailing twelve-month basis.

When is the next Zimmer Biomet dividend payment date?

The next Zimmer Biomet (ZBH) dividend payment is scheduled for April 30, 2024.

What is the beta indicator for Zimmer Biomet?

Zimmer Biomet (ZBH) has a beta rating of 1.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Zimmer Biomet stock price target?

The target price for Zimmer Biomet (ZBH) stock is $137.17, which is 13.57% above the current price of $120.78. This is an average based on projections from 23 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Zimmer Biomet stock

Buy or sell Zimmer Biomet stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing